Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $480.79 million. The enterprise value is $518.03 million.
| Market Cap | 480.79M |
| Enterprise Value | 518.03M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 65.32 million shares outstanding. The number of shares has increased by 7.30% in one year.
| Current Share Class | 53.36M |
| Shares Outstanding | 65.32M |
| Shares Change (YoY) | +7.30% |
| Shares Change (QoQ) | +4.35% |
| Owned by Insiders (%) | 15.42% |
| Owned by Institutions (%) | 49.42% |
| Float | 47.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.18 |
| Forward PS | 4.26 |
| PB Ratio | 1.02 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.15, with a Debt / Equity ratio of 0.93.
| Current Ratio | 5.15 |
| Quick Ratio | 4.95 |
| Debt / Equity | 0.93 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.03% and return on invested capital (ROIC) is -19.42%.
| Return on Equity (ROE) | -56.03% |
| Return on Assets (ROA) | -16.16% |
| Return on Invested Capital (ROIC) | -19.42% |
| Return on Capital Employed (ROCE) | -31.22% |
| Weighted Average Cost of Capital (WACC) | 7.57% |
| Revenue Per Employee | $312,163 |
| Profits Per Employee | -$627,614 |
| Employee Count | 485 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.01M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.95% in the last 52 weeks. The beta is 1.78, so DNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.78 |
| 52-Week Price Change | -47.95% |
| 50-Day Moving Average | 8.71 |
| 200-Day Moving Average | 9.02 |
| Relative Strength Index (RSI) | 35.06 |
| Average Volume (20 Days) | 1,068,397 |
Short Selling Information
The latest short interest is 5.21 million, so 7.97% of the outstanding shares have been sold short.
| Short Interest | 5.21M |
| Short Previous Month | 4.91M |
| Short % of Shares Out | 7.97% |
| Short % of Float | 10.88% |
| Short Ratio (days to cover) | 4.56 |
Income Statement
In the last 12 months, DNA had revenue of $151.40 million and -$304.39 million in losses. Loss per share was -$5.36.
| Revenue | 151.40M |
| Gross Profit | 105.42M |
| Operating Income | -300.76M |
| Pretax Income | -306.52M |
| Net Income | -304.39M |
| EBITDA | -240.70M |
| EBIT | -297.68M |
| Loss Per Share | -$5.36 |
Balance Sheet
The company has $373.46 million in cash and $410.70 million in debt, with a net cash position of -$37.24 million or -$0.57 per share.
| Cash & Cash Equivalents | 373.46M |
| Total Debt | 410.70M |
| Net Cash | -37.24M |
| Net Cash Per Share | -$0.57 |
| Equity (Book Value) | 443.15M |
| Book Value Per Share | 7.19 |
| Working Capital | 330.36M |
Cash Flow
In the last 12 months, operating cash flow was -$166.22 million and capital expenditures -$1.98 million, giving a free cash flow of -$168.20 million.
| Operating Cash Flow | -166.22M |
| Capital Expenditures | -1.98M |
| Depreciation & Amortization | 38.27M |
| Net Borrowing | -166,000 |
| Free Cash Flow | -168.20M |
| FCF Per Share | -$2.57 |
Margins
Gross margin is 69.63%, with operating and profit margins of -198.65% and -201.05%.
| Gross Margin | 69.63% |
| Operating Margin | -198.65% |
| Pretax Margin | -202.46% |
| Profit Margin | -201.05% |
| EBITDA Margin | -197.56% |
| EBIT Margin | -244.33% |
| FCF Margin | n/a |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.30% |
| Shareholder Yield | -7.30% |
| Earnings Yield | -63.31% |
| FCF Yield | -34.98% |
Analyst Forecast
The average price target for DNA is $8.50, which is 15.49% higher than the current price. The consensus rating is "Hold".
| Price Target | $8.50 |
| Price Target Difference | 15.49% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 20.32% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:40.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
DNA has an Altman Z-Score of -8.32 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.32 |
| Piotroski F-Score | 2 |